Voyager Therapeutics entered a strategic collaboration and capsid license agreement with Novartis to advance potential gene therapies for Huntington’s disease and spinal muscular atrophy, providing Novartis a target-exclusive license to access its TRACER capsids and other intellectual property.
Novartis obtains target-exclusive access to Voyager’s TRACER capsids related to Huntington’s disease and spinal muscular atrophy.
Leave a reply